manifest: pelabresib updates
Published 3 years ago • 63 plays • Length 3:55Download video MP4
Download video MP3
Similar videos
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
2:10
manifest update: pelabresib clinical and pathological investigations
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
3:49
manifest: pelabresib (cpi-0610) ruxolitinib in advanced myelofibrosis patients
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
9:57
quadruplet therapies for treating mm: the current evidence and the findings of a phase ii trial
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
3:21
manifest: ruxolitinib plus pelabresib for jak-inhibitor naïve myelofibrosis
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
3:33
manifest: pelabresib (cpi-0610) shows promise in myelofibrosis
-
1:30
insights into the manifest-2 study
-
1:49
results from manifest phase ii study of pelabresib for anemia associated with myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
3:06
manifest study of pelabresib (cpi-0610) in myelofibrosis
-
1:00
the promising role of pelabresib in the treatment of mf
-
3:02
durability of response & biomarker changes in the manifest study
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t